LT4920B - Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui - Google Patents

Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui Download PDF

Info

Publication number: LT4920B
Authority: LT; Lithuania
Prior art keywords: agent; composition; antibody; cell; factor viii
Prior art date: 1998-09-21

Application number

LT2001045A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2001045A (en

Inventor

Jiahua Qian

Leon W. Hoyer

Mary Collins

Gary S. Gray

Original Assignee

Genetics Institute,Inc.

American Red Cross

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-21

Filing date

2001-04-20

Publication date

2002-06-25

2001-04-20 Application filed by Genetics Institute,Inc., American Red Cross filed Critical Genetics Institute,Inc.

2002-01-25 Publication of LT2001045A publication Critical patent/LT2001045A/xx

2002-06-25 Publication of LT4920B publication Critical patent/LT4920B/lt

Links

239000000203 mixture Substances 0.000 title claims abstract description 89
230000028993 immune response Effects 0.000 title claims abstract description 48
108090000623 proteins and genes Proteins 0.000 title abstract description 87
102000004169 proteins and genes Human genes 0.000 title abstract description 75
230000001225 therapeutic effect Effects 0.000 title abstract description 16
230000000139 costimulatory effect Effects 0.000 claims abstract description 202
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 93
208000024659 Hemostatic disease Diseases 0.000 claims abstract description 35
238000011282 treatment Methods 0.000 claims abstract description 32
208000012908 vascular hemostatic disease Diseases 0.000 claims abstract description 32
230000023597 hemostasis Effects 0.000 claims abstract description 31
239000003795 chemical substances by application Substances 0.000 claims description 192
229960000301 factor viii Drugs 0.000 claims description 130
108010054218 Factor VIII Proteins 0.000 claims description 106
102000001690 Factor VIII Human genes 0.000 claims description 105
102100022641 Coagulation factor IX Human genes 0.000 claims description 34
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 34
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 33
108010076282 Factor IX Proteins 0.000 claims description 29
229960004222 factor ix Drugs 0.000 claims description 25
201000003542 Factor VIII deficiency Diseases 0.000 claims description 24
208000009292 Hemophilia A Diseases 0.000 claims description 24
108010029697 CD40 Ligand Proteins 0.000 claims description 22
102100032937 CD40 ligand Human genes 0.000 claims description 22
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 22
102100036537 von Willebrand factor Human genes 0.000 claims description 22
101150013553 CD40 gene Proteins 0.000 claims description 19
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 19
229940030225 antihemorrhagics Drugs 0.000 claims description 18
230000000025 haemostatic effect Effects 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
208000009429 hemophilia B Diseases 0.000 claims description 10
102100026735 Coagulation factor VIII Human genes 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 6
208000027276 Von Willebrand disease Diseases 0.000 claims description 5
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 5
230000003213 activating effect Effects 0.000 claims description 4
108010047303 von Willebrand Factor Proteins 0.000 claims description 4
229960001134 von willebrand factor Drugs 0.000 claims description 4
229940125721 immunosuppressive agent Drugs 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 79
238000000034 method Methods 0.000 description 78
210000004027 cell Anatomy 0.000 description 62
230000002163 immunogen Effects 0.000 description 32
238000002347 injection Methods 0.000 description 30
239000007924 injection Substances 0.000 description 30
230000000694 effects Effects 0.000 description 29
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 28
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 28
108090000765 processed proteins & peptides Proteins 0.000 description 28
210000004408 hybridoma Anatomy 0.000 description 27
241001465754 Metazoa Species 0.000 description 25
101150045640 VWF gene Proteins 0.000 description 18
239000012634 fragment Substances 0.000 description 17
210000000612 antigen-presenting cell Anatomy 0.000 description 16
208000031220 Hemophilia Diseases 0.000 description 15
230000002401 inhibitory effect Effects 0.000 description 15
150000001413 amino acids Chemical group 0.000 description 14
210000003719 b-lymphocyte Anatomy 0.000 description 14
108020001507 fusion proteins Proteins 0.000 description 14
102000037865 fusion proteins Human genes 0.000 description 14
150000007523 nucleic acids Chemical class 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
102000057593 human F8 Human genes 0.000 description 13
239000003446 ligand Substances 0.000 description 13
108020004707 nucleic acids Proteins 0.000 description 13
102000039446 nucleic acids Human genes 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 12
230000003053 immunization Effects 0.000 description 12
238000002649 immunization Methods 0.000 description 12
239000003112 inhibitor Substances 0.000 description 12
230000003993 interaction Effects 0.000 description 12
238000010561 standard procedure Methods 0.000 description 12
108091007960 PI3Ks Proteins 0.000 description 11
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 11
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000000427 antigen Substances 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
238000003556 assay Methods 0.000 description 11
229960000900 human factor viii Drugs 0.000 description 11
229940090044 injection Drugs 0.000 description 11
230000005867 T cell response Effects 0.000 description 10
230000006870 function Effects 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
230000004044 response Effects 0.000 description 10
230000011664 signaling Effects 0.000 description 10
-1 succinimidyl Chemical group 0.000 description 10
108010021064 CTLA-4 Antigen Proteins 0.000 description 9
102000008203 CTLA-4 Antigen Human genes 0.000 description 9
239000002269 analeptic agent Substances 0.000 description 9
230000005875 antibody response Effects 0.000 description 9
229940005779 factor viii injection Drugs 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
241000124008 Mammalia Species 0.000 description 8
206010035226 Plasma cell myeloma Diseases 0.000 description 8
230000004913 activation Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
201000000050 myeloid neoplasm Diseases 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
208000032843 Hemorrhage Diseases 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 7
230000006052 T cell proliferation Effects 0.000 description 7
239000002671 adjuvant Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000036039 immunity Effects 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
210000004989 spleen cell Anatomy 0.000 description 7
239000013598 vector Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
230000020385 T cell costimulation Effects 0.000 description 6
239000010836 blood and blood product Substances 0.000 description 6
229940125691 blood product Drugs 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
230000004940 costimulation Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
230000006058 immune tolerance Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
150000003905 phosphatidylinositols Chemical class 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
230000001737 promoting effect Effects 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
230000007017 scission Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
241000894007 species Species 0.000 description 6
239000000126 substance Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
241001529936 Murinae Species 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 5
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
239000013543 active substance Substances 0.000 description 5
208000034158 bleeding Diseases 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
210000002865 immune cell Anatomy 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
238000010253 intravenous injection Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
244000005700 microbiome Species 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
239000013615 primer Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 4
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 4
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
238000000576 coating method Methods 0.000 description 4
230000016396 cytokine production Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000013401 experimental design Methods 0.000 description 4
MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical group N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108020000494 protein-tyrosine phosphatase Proteins 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
239000011734 sodium Substances 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
102100023804 Coagulation factor VII Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010023321 Factor VII Proteins 0.000 description 3
102000004140 Oncostatin M Human genes 0.000 description 3
108090000630 Oncostatin M Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
108010071390 Serum Albumin Proteins 0.000 description 3
102000007562 Serum Albumin Human genes 0.000 description 3
230000003321 amplification Effects 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
210000000628 antibody-producing cell Anatomy 0.000 description 3
229940121375 antifungal agent Drugs 0.000 description 3
239000003429 antifungal agent Substances 0.000 description 3
239000002981 blocking agent Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
229940012413 factor vii Drugs 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108010045634 B7 Antigens Proteins 0.000 description 2
102000005738 B7 Antigens Human genes 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
239000004971 Cross linker Substances 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010048049 Factor IXa Proteins 0.000 description 2
108010014173 Factor X Proteins 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
241000237858 Gastropoda Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical group C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
102000014384 Type C Phospholipases Human genes 0.000 description 2
108010079194 Type C Phospholipases Proteins 0.000 description 2
102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
229940037003 alum Drugs 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000009510 drug design Methods 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
108060003552 hemocyanin Proteins 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
239000003921 oil Substances 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
150000003243 quercetin Chemical class 0.000 description 2
150000003244 quercetin derivatives Chemical class 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241001146702 Candidatus Entotheonella factor Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000393427 Cepaea hortensis Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108030004793 Dual-specificity kinases Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010016077 Factor IX deficiency Diseases 0.000 description 1
229940124135 Factor VIII inhibitor Drugs 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
241000724791 Filamentous phage Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101100156611 Homo sapiens VWF gene Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 1
102100034980 ICOS ligand Human genes 0.000 description 1
101710093458 ICOS ligand Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010056902 Mononine Proteins 0.000 description 1
101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 1
101100192367 Mus musculus Ptpn6 gene Proteins 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
239000012828 PI3K inhibitor Substances 0.000 description 1
101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
208000018239 Reduced factor VIII activity Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
241001136485 Talaromyces wortmannii Species 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
229940031422 benefix Drugs 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
229940027029 hemofil Drugs 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
230000006266 hibernation Effects 0.000 description 1
229940099816 human factor vii Drugs 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000036046 immunoreaction Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006057 immunotolerant effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
229940047434 kogenate Drugs 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940090053 mononine Drugs 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
108091005981 phosphorylated proteins Proteins 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
108010025139 recombinant factor VIII SQ Proteins 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
229940047431 recombinate Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LT2001045A 1998-09-21 2001-04-20 Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui LT4920B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15817898A	1998-09-21	1998-09-21

Publications (2)

Publication Number	Publication Date
LT2001045A LT2001045A (en)	2002-01-25
LT4920B true LT4920B (lt)	2002-06-25

Family

ID=22566971

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2001045A LT4920B (lt)	1998-09-21	2001-04-20	Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui

Country Status (21)

Country	Link
EP (1)	EP1115423A1 (pt)
JP (1)	JP2002526455A (pt)
KR (1)	KR20010085830A (pt)
CN (1)	CN1331602A (pt)
AU (1)	AU761206B2 (pt)
BR (1)	BR9913991A (pt)
CA (1)	CA2343916A1 (pt)
CZ (1)	CZ20011021A3 (pt)
EA (1)	EA005236B1 (pt)
HK (1)	HK1039059A1 (pt)
HU (1)	HUP0103960A3 (pt)
IL (1)	IL142069A0 (pt)
LT (1)	LT4920B (pt)
LV (1)	LV12768B (pt)
MX (1)	MXPA01002898A (pt)
NO (1)	NO20011412L (pt)
NZ (1)	NZ511034A (pt)
PL (1)	PL346796A1 (pt)
SI (1)	SI20626A (pt)
WO (1)	WO2000016801A1 (pt)
ZA (1)	ZA200103156B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
AU2001261735B2 (en) *	2000-05-19	2006-09-21	The Center For Blood Research, Inc.	Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
EP1636579A4 (en) *	2003-06-10	2011-10-05	Smiths Detection Inc	SENSOR ASSEMBLY
GB201508024D0 (en) *	2015-05-11	2015-06-24	Haemostatix Ltd	Haemostatic compositions

Citations (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4868112A (en)	1985-04-12	1989-09-19	Genetics Institute, Inc.	Novel procoagulant proteins
US4994371A (en)	1987-08-28	1991-02-19	Davie Earl W	DNA preparation of Christmas factor and use of DNA sequences
US5171569A (en)	1985-03-15	1992-12-15	National Research Development Corporation	Factor IX preparations uncontaminated by plasma components or pox virus
WO1993000431A1 (en)	1991-06-27	1993-01-07	Bristol-Myers Squibb Company	Ctl4a receptor, fusion proteins containing it and uses thereof
US5422260A (en)	1986-05-29	1995-06-06	Genetics Institute, Inc. -Legal Affairs	Human factor VIII:c muteins
US5583209A (en)	1992-04-07	1996-12-10	Emory University	Hybrid human/porcine factor VIII
US5621039A (en)	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
US5661008A (en)	1991-03-15	1997-08-26	Kabi Pharmacia Ab	Recombinant human factor VIII derivatives
US5663060A (en)	1992-04-07	1997-09-02	Emory University	Hybrid human/animal factor VIII
US5679639A (en)	1991-11-18	1997-10-21	The Scripps Research Institute	Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5707832A (en)	1990-02-05	1998-01-13	Tm Innovation	Process for the preparation of human factor VIII and analogs of factor VIII
US5714583A (en)	1995-06-07	1998-02-03	Genetics Institute, Inc.	Factor IX purification methods
US5744446A (en)	1992-04-07	1998-04-28	Emory University	Hybrid human/animal factor VIII
US5770197A (en)	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US8701299B2 (en)	2009-11-06	2014-04-22	Hexagon Metrology Ab	CMM with modular functionality

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0776217A1 (en) *	1994-08-19	1997-06-04	Novo Nordisk A/S	A method of treating a patient with a biologically active compound
CA2200869A1 (en) *	1994-10-19	1996-05-02	Bruce C. Trapnell	Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
WO1997034633A1 (en) *	1996-03-20	1997-09-25	Bristol-Myers Squibb Company	Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
CZ244399A3 (cs) *	1997-01-10	1999-10-13	Biogen, Inc.	Použití sloučeniny anti-CD40L pro výrobu léku pro léčení imunologických onemocnění
IL133305A0 (en) *	1997-06-20	2001-04-30	Biogen Inc	Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome

1999
- 1999-09-21 CA CA002343916A patent/CA2343916A1/en not_active Abandoned
- 1999-09-21 IL IL14206999A patent/IL142069A0/xx unknown
- 1999-09-21 PL PL99346796A patent/PL346796A1/xx not_active Application Discontinuation
- 1999-09-21 BR BR9913991-0A patent/BR9913991A/pt not_active IP Right Cessation
- 1999-09-21 HU HU0103960A patent/HUP0103960A3/hu unknown
- 1999-09-21 MX MXPA01002898A patent/MXPA01002898A/es unknown
- 1999-09-21 WO PCT/US1999/021991 patent/WO2000016801A1/en not_active Ceased
- 1999-09-21 EP EP99969339A patent/EP1115423A1/en not_active Withdrawn
- 1999-09-21 CN CN99813510A patent/CN1331602A/zh active Pending
- 1999-09-21 HK HK02100157.7A patent/HK1039059A1/zh unknown
- 1999-09-21 SI SI9920084A patent/SI20626A/sl not_active IP Right Cessation
- 1999-09-21 AU AU60578/99A patent/AU761206B2/en not_active Ceased
- 1999-09-21 NZ NZ511034A patent/NZ511034A/xx unknown
- 1999-09-21 KR KR1020017003611A patent/KR20010085830A/ko not_active Withdrawn
- 1999-09-21 CZ CZ20011021A patent/CZ20011021A3/cs unknown
- 1999-09-21 EA EA200100385A patent/EA005236B1/ru not_active IP Right Cessation
- 1999-09-21 JP JP2000573762A patent/JP2002526455A/ja not_active Withdrawn
2001
- 2001-03-20 NO NO20011412A patent/NO20011412L/no not_active Application Discontinuation
- 2001-04-18 ZA ZA200103156A patent/ZA200103156B/xx unknown
- 2001-04-20 LV LVP-01-62A patent/LV12768B/lv unknown
- 2001-04-20 LT LT2001045A patent/LT4920B/lt not_active IP Right Cessation

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5171569A (en)	1985-03-15	1992-12-15	National Research Development Corporation	Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en)	1985-04-12	1989-09-19	Genetics Institute, Inc.	Novel procoagulant proteins
US5422260A (en)	1986-05-29	1995-06-06	Genetics Institute, Inc. -Legal Affairs	Human factor VIII:c muteins
US4994371A (en)	1987-08-28	1991-02-19	Davie Earl W	DNA preparation of Christmas factor and use of DNA sequences
US5707832A (en)	1990-02-05	1998-01-13	Tm Innovation	Process for the preparation of human factor VIII and analogs of factor VIII
US5661008A (en)	1991-03-15	1997-08-26	Kabi Pharmacia Ab	Recombinant human factor VIII derivatives
WO1993000431A1 (en)	1991-06-27	1993-01-07	Bristol-Myers Squibb Company	Ctl4a receptor, fusion proteins containing it and uses thereof
US5770197A (en)	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5679639A (en)	1991-11-18	1997-10-21	The Scripps Research Institute	Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5663060A (en)	1992-04-07	1997-09-02	Emory University	Hybrid human/animal factor VIII
US5744446A (en)	1992-04-07	1998-04-28	Emory University	Hybrid human/animal factor VIII
US5583209A (en)	1992-04-07	1996-12-10	Emory University	Hybrid human/porcine factor VIII
US5621039A (en)	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
US5714583A (en)	1995-06-07	1998-02-03	Genetics Institute, Inc.	Factor IX purification methods
US8701299B2 (en)	2009-11-06	2014-04-22	Hexagon Metrology Ab	CMM with modular functionality

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BLUESTONE JA: "New perspectives of CD28-B7-mediated T cell costimulation", IMMUNITY., 1995, pages 555
C. D. GIMMI ET AL.: "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2", PROC NATL ACAD SCI USA., 1991, pages 6575 - 6579
C. H. JUNE ET AL.: "Role of the CD28 receptor in T cell activation", IMMUNOL. TODAY., 1990, pages 211 - 216, XP026942223, DOI: doi:10.1016/0167-5699(90)90085-N
CONNELLY S, MOUNT J, MAUSER A, ET AL.: "Complete short-term correction of canine hemophilia A by in vivo gene therapy", BLOOD, 1996, pages 3846, XP002926495
D. J. LENSCHOW ET AL.: "CD28/B7 system of T cell costimulation", ANNU REV IMMUNOL., 1996, pages 233, XP000916005, DOI: doi:10.1146/annurev.immunol.14.1.233
F. HARDING ET AL.: "CD28-mediated signaling costimulates murine T cells and prevents the induction of anergy in T cell clones", NATURE, 1992, pages 607 - 609
G. J. FREEMAN ET AL.: "B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells", THE JOURNAL OF IMMUNOLOGY, 1991, pages 2714
G. J. FREEMAN ET AL.: "Cloning of B7-2: CTLA-4 counter-receptor that costimulates human T cell proliferation", SCIENCE, 1993, pages 909, XP002069402, DOI: doi:10.1126/science.7694363
G. J. FREEMAN ET AL.: "Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7", J EXP MED., 1991, pages 625, XP000608218, DOI: doi:10.1084/jem.174.3.625
H. REISER ET AL.: "Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex", PROC NATL ACAD SCI USA., 1992, pages 271 - 275
ISSELBACHER ET AL.: "Harrisons Principles of Internal Medicine, 13th Ed."
J. F. BRUNET ET AL.: "A new member of the immunoglobulin superfamily: CTLA-4", NATURE, 1987, pages 267 - 270, XP002915323, DOI: doi:10.1038/328267a0
J. W. YOUNG ET AL.: "The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro", J CLIN INVEST., 1992, pages 229 - 237
JENKINS MK, ASHWELL JD, SCHWARTZ RH: "Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells", J IMMUNOL., 1988, pages 3324 - 3330
L. KOULOVA: "The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells", J EXP MED., 1991, pages 759 - 762
LASALLE JM, OTA K, HAFLER DA: "Presentation of autoantigen by human T cells", J IMMUNOL., 1991, pages 774 - 780
M. JENKINS, R. SCHWARTZ: "Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo", J EXP MED., 1987, pages 302 - 319, XP000877390, DOI: doi:10.1084/jem.165.2.302
M. L. DUSTIN ET AL.: "Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3.", J. EXP. MED, 1989, pages 503
MUELLER DL, JENKINS MK, CHIODETTI L, SCHWARTZ: "An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory signal", J IMMUNOL., 1990, pages 3701 - 3709
P. S. LINSLEY ET AT.: "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation", J EXP MED., 1991, pages 721 - 730, XP000611265, DOI: doi:10.1084/jem.173.3.721
R. J. ARMITAGE ET AL.: "Molecular and biological characterization of a murine ligand for CD40", NATURE, 1992, pages 80 - 82, XP002024662, DOI: doi:10.1038/357080a0
VAN SEVENTER GA ET AL.: "The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells", J IMMUNOL., 1990, pages 4579 - 4586
Y. LIU ET AL.: "Heat-stable antigen is a constimulatory molecule for CD4 T cell growth", J. EXP. MED., 1992, pages 437 - 445

Also Published As

Publication number	Publication date
EA200100385A1 (ru)	2001-10-22
HK1039059A1 (zh)	2002-04-12
CA2343916A1 (en)	2000-03-30
MXPA01002898A (es)	2002-06-04
EP1115423A1 (en)	2001-07-18
HUP0103960A2 (hu)	2002-02-28
SI20626A (sl)	2002-02-28
LT2001045A (en)	2002-01-25
LV12768B (lv)	2002-06-20
IL142069A0 (en)	2002-03-10
BR9913991A (pt)	2001-07-03
ZA200103156B (en)	2002-07-18
AU6057899A (en)	2000-04-10
KR20010085830A (ko)	2001-09-07
CZ20011021A3 (cs)	2001-10-17
JP2002526455A (ja)	2002-08-20
NO20011412L (no)	2001-05-16
LV12768A (en)	2001-12-20
PL346796A1 (en)	2002-02-25
AU761206B2 (en)	2003-05-29
CN1331602A (zh)	2002-01-16
NO20011412D0 (no)	2001-03-20
NZ511034A (en)	2004-03-26
HUP0103960A3 (en)	2003-09-29
WO2000016801A9 (en)	2000-10-26
WO2000016801A1 (en)	2000-03-30
EA005236B1 (ru)	2004-12-30

Publication	Publication Date	Title
Qian et al.	2000	Prevention and treatment of factor VIII inhibitors in murine hemophilia A
AU709711B2 (en)	1999-09-02	Methods for modulating T cell unresponsiveness
US20120269806A1 (en)	2012-10-25	Methods of inducing tolerance
JP5580535B2 (ja)	2014-08-27	癌転移および癌転移に関連する骨量減少を予防および処置するための方法
US11547741B2 (en)	2023-01-10	Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
Qian et al.	2000	Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer
US12319744B2 (en)	2025-06-03	Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
US20080095774A1 (en)	2008-04-24	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
Saenko et al.	2002	Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action
US20210340214A1 (en)	2021-11-04	Cd80 extracellular domain fc fusion protein dosing regimens
BG64436B1 (en)	2005-02-28	Cd154 blockade therapy for the treatment of protein inhibition syndrome
KR102165486B1 (ko)	2020-10-15	펩타이드
AU761206B2 (en)	2003-05-29	Methods of downmodulating the immune response to therapeutic proteins
Fijnvandraat et al.	2003	Immunobiology of inhibitor development in hemophilia A
KR20230038658A (ko)	2023-03-21	Adamts13 단백질 변형체 및 그것의 용도
US20030161827A1 (en)	2003-08-28	Therapies that improve graft survival
US20230023174A1 (en)	2023-01-26	Cd80 extracellular domain fc fusion protein regimens
US20020071839A1 (en)	2002-06-13	Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Miao et al.	0	Immunomodulation of transgene responses following naked DNA transfer
Erkan et al.	2012	What are the Potential Future Treatments in Antiphospholipid Syndrome?
HK40024980A (en)	2020-12-18	Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
AU3437902A (en)	2002-06-06	Methods for modulating T cell unresponsiveness

Legal Events

Date	Code	Title	Description
2004-02-25	PD9A	Change of patent owner	Owner name: AMERICAN RED CROSS, US Free format text: FORMEROWNER: GENETICS INSTITUTE, LLC, US Effective date: 20031223
2006-05-25	MM9A	Lapsed patents	Effective date: 20050921

Date

Code

Title

Description

2004-02-25

PD9A

Change of patent owner

Owner name: AMERICAN RED CROSS, US

Free format text: FORMEROWNER: GENETICS INSTITUTE, LLC, US

Effective date: 20031223

2006-05-25

MM9A

Lapsed patents

Effective date: 20050921